Status Discontinued
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information Following on from information provided to NICE by the company in November 2015, the appraisal of Leukaemia (acute lymphoblastic, Philadelphia negative) - vincristine liposomal (after 2 therapies) [ID954] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
Process TA
ID number 954

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
17 November 2022 Following on from information provided to NICE by the company in November 2015, the appraisal of Leukaemia (acute lymphoblastic, Philadelphia negative) - vincristine liposomal (after 2 therapies) [ID954] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
17 November 2022 Discontinued

For further information on our processes and methods, please see our CHTE processes and methods manual